The company is increasing guidance for the U.S. Thrombectomy franchise growth to 20% to 21% year over year from 19% to 20% previously. The company reiterates guidance for gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to a range of 13% to 14% of revenue for full year 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra Inc. (PEN) Q1 Earnings Cheat Sheet
- Cautious Outlook on Penumbra’s Thunderbolt Amid Trial Uncertainty and Market Delay
- Penumbra price target raised to $315 from $313 at RBC Capital
- Penumbra price target lowered to $305 from $308 at BTIG
- Penumbra price target lowered to $315 from $325 at Truist